Cerenome (CNSY) is expected to report a Q3 2026 consensus loss of $0.98 per share on revenue of $0.75 million, with the stock currently trading at $1.58 relative to an average analyst price target of $27.75.
Investors are primarily focused on the commercial ramp-up of the CNSide diagnostic platform and the company's ability to convert its reported $1.55 million in Q3 gross billings into recognized GAAP revenue.
Beyond financial results, the market is awaiting clinical updates for the ReSPECT-LM trial of lead radiotherapeutic candidate REYOBIQ, which is on track for a Q3 data release. Recent milestones include securing a $20 million financing facility and expanding CNSide insurance coverage to approximately 158 million lives.